Is Money the Cure-All? Seattle-area biotech companies are striking deals, but questions loom about the market’s access to talent
Despite an economic downturn, investment in Seattle’s biotech industry hasn’t slowed down this year. With Athira Pharma’s September IPO that raised $204 million, life science companies in the region are proving that continued growth is very much on the table. With expansions in size comes an increased hiring demand, too, and attracting out-of-area biotech talent and new individuals to the industry is key.
“The demand for talent is greater than it’s ever been, and the competition for that talent is greater than it’s ever been,” said Leslie Alexandre, Life Science Washington President and CEO. “What we have is in many respects a good problem. It’s the problem you want to have in a thriving ecosystem.”